Association/NN
Analysis/NN
of/IN
SERPINB5/NN
Polymorphisms/NNS
with/IN
HBV/NN
Clearance/NN
and/CC
HCC/NN
Occurrence/NN
in/IN
a/DT
Korean/JJ
Population/NN
./.
====================
Serpin/NN
peptidase/NN
inhibitor/NN
,/,
Clade/NN
B/NN
(/(
ovalbumin/NN
)/)
,/,
Member/NN
5/CD
(/(
SERPINB5/NN
)/)
,/,
also/RB
known/VBN
as/IN
maspin/NN
,/,
is/VBZ
a/DT
potent/JJ
tumor/NN
suppressor/NN
gene/NN
./.
====================
It/PRP
has/VBZ
correlations/NNS
with/IN
many/JJ
tumor/NN
cells/NNS
,/,
from/IN
pancreas/NN
cancer/NN
to/TO
breast/NN
cancer/NN
,/,
so/RB
it/PRP
is/VBZ
possible/JJ
that/IN
it/PRP
may/MD
also/RB
affect/VB
liver/NN
cancer/NN
./.
====================
There/EX
has/VBZ
also/RB
been/VBN
a/DT
report/NN
that/IN
SERPINB12/NN
,/,
a/DT
gene/NN
placed/VBN
right/JJ
next/RB
to/TO
SERPINB5/NN
,/,
is/VBZ
expressed/VBN
in/IN
liver/NN
./.
====================
For/IN
this/DT
study/NN
,/,
32/CD
polymorphisms/NNS
were/VBD
identified/VBN
in/IN
SERPINB5/NN
by/IN
direct/JJ
DNA/NN
sequencing/NN
,/,
and/CC
11/CD
of/IN
them/PRP
were/VBD
selected/VBN
to/TO
be/VB
tested/VBN
with/IN
a/DT
larger/RBR
scale/JJ
subjects/NNS
./.
====================
The/DT
association/NN
of/IN
the/DT
11/CD
SERPINB5/NN
polymorphisms/NNS
with/IN
Hepatitis/NN
B/NN
virus/NN
(/(
HBV/NN
)/)
clearance/NN
,/,
hepatocellular/JJ
carcinoma/NN
(/(
HCC/NN
)/)
occurrence/VBP
and/CC
the/DT
onset/NN
age/NN
of/IN
HCC/NN
were/VBD
analyzed/VBN
./.
====================
There/EX
were/VBD
no/DT
significant/JJ
associations/NNS
found/VBN
between/IN
11/CD
SERPINB5/NN
polymorphisms/NNS
and/CC
HBV/NN
clearance/NN
./.
====================
In/IN
the/DT
case/NN
of/IN
HCC/NN
occurrence/NN
,/,
one/CD
of/IN
the/DT
haplotypes/NNS
(/(
ht/NN
)/)
showed/VBD
association/NN
with/IN
HCC/NN
occurrence/NN
(/(
OR=2.26/CD
,/,
p=0.005/NN
,/,
PCor=0.05/NN
)/)
,/,
albeit/IN
with/IN
a/DT
low/JJ
statistical/JJ
power/JJR
(/(
40.8/CD
%/NN
)/)
and/CC
haplotype/JJ
frequency/NN
(/(
0.052/CD
)/)
./.
====================
Further/RB
study/NN
with/IN
a/DT
bigger/JJR
sample/NN
size/NN
will/MD
be/VB
needed/VBN
to/TO
clearly/RB
verify/RB
the/DT
association/NN
between/IN
ht5/NN
and/CC
HCC/NN
occurrence/NN
./.
====================
Hepatitis/NN
B/NN
virus/NN
(/(
HBV/NN
)/)
infection/NN
is/VBZ
one/CD
of/IN
the/DT
more/RBR
common/JJ
diseases/NNS
worldwide/NN
,/,
with/IN
more/RBR
than/IN
360/CD
million/NN
chronic/JJ
carriers/NNS
(/(
Kane/NN
,/,
1998/CD
)/)
./.
====================
It/PRP
particularly/RB
affects/VBZ
Asia/NN
,/,
Africa/NNP
,/,
Southern/NN
Europe/NN
and/CC
South/NN
America/NNP
(/(
Lin/JJ
&/CC
Kao/NN
,/,
2008/CD
)/)
,/,
and/CC
South/NN
Korea/NN
is/VBZ
no/DT
exception/NN
to/TO
the/DT
virus/NN
,/,
as/IN
it/PRP
is/VBZ
an/DT
endemic/JJ
area/NN
of/IN
the/DT
Hepatitis/NN
B/NN
virus/NN
./.
====================
There/EX
are/VBP
several/JJ
directions/NNS
for/IN
clinical/JJ
course/NN
of/IN
HBV/NN
infection/NN
,/,
from/IN
spontaneous/JJ
recovery/NN
to/TO
chronic/JJ
infection/NN
,/,
which/WDT
may/MD
further/RBR
develop/VBP
to/TO
liver/NN
cirrhosis/NN
and/CC
hepatocellular/JJ
carcinoma/NN
./.
====================
Age/NN
at/IN
infection/NN
is/VBZ
a/DT
crucial/JJ
factor/NN
on/IN
clinical/JJ
outcome/NN
./.
====================
Most/JJS
HBV/NN
infection/NN
occurs/VBZ
at/IN
birth/NN
or/CC
within/IN
5/CD
years/NNS
after/IN
the/DT
birth/NN
,/,
and/CC
they/PRP
also/RB
become/VBP
chronic/JJ
carriers/NNS
./.
====================
HBV/NN
causes/VBZ
not/RB
only/RB
Hepatitis/NN
B/NN
;/:
chronic/JJ
infection/NN
of/IN
the/DT
virus/NN
could/MD
also/RB
lead/VBP
to/TO
liver/NN
cirrhosis/NN
(/(
LC/NN
)/)
and/CC
hepatocellular/JJ
carcinoma/NN
(/(
HCC/NN
)/)
./.
====================
It/PRP
has/VBZ
been/VBN
noted/VBN
that/IN
HBV/NN
carriers/NNS
have/VBP
as/IN
much/RB
as/IN
100/CD
times/NNS
the/DT
risk/NN
of/IN
developing/VBG
HCC/NN
than/IN
noncarriers/NNS
(/(
Koshy/NN
,/,
1998/CD
)/)
./.
====================
Hepatocellular/JJ
carcinoma/NN
is/VBZ
a/DT
primary/JJ
cancer/NN
type/NN
of/IN
liver/NN
./.
====================
HCC/NN
usually/RB
develops/VBZ
after/IN
HBV/NN
infection/NN
or/CC
development/NN
of/IN
LC/NN
and/CC
is/VBZ
one/CD
of/IN
the/DT
most/JJS
common/JJ
types/NNS
of/IN
tumors/NNS
worldwide/NN
./.
====================
It/PRP
generally/RB
affects/VBZ
men/NNS
more/RBR
than/IN
women/NNS
,/,
and/CC
the/DT
age/NN
of/IN
onset/NN
is/VBZ
usually/RB
between/IN
30s/NNS
to/TO
50s/JJ
(/(
Kumar/JJ
V/JJ
,/,
2003/CD
)/)
./.
====================
Pathogenesis/NN
of/IN
HCC/NN
is/VBZ
similar/JJ
to/TO
other/JJ
types/NNS
of/IN
cancers/NNS
in/IN
that/DT
HCC/NN
develops/VBZ
when/WRB
a/DT
mutation/NN
occurs/VBZ
at/IN
cellular/JJ
machinery/NN
which/WDT
results/VBZ
in/IN
faster/JJR
replication/NN
of/IN
the/DT
cell/NN
and/or/CC
nullification/NN
of/IN
apoptosis/NN
./.
====================
Chronic/JJ
infection/NN
of/IN
Hepatitis/NN
B/NN
or/CC
C/NN
virus/NN
aids/NNS
the/DT
development/NN
of/IN
HCC/NN
because/IN
the/DT
viruses/NNS
cause/VBP
the/DT
immune/JJ
system/NN
to/TO
attack/VB
the/DT
body/NN
’/NN
s/NNS
own/JJ
liver/NN
cell/NN
./.
====================
This/DT
cycle/NN
of/IN
constant/JJ
damaging/NN
and/CC
repair/NN
can/MD
lead/VB
to/TO
mistakes/NNS
which/WDT
may/MD
then/RB
result/VBP
in/IN
carcinogenesis/NN
./.
====================
Recently/RB
,/,
it/PRP
has/VBZ
been/VBN
suggested/VBN
that/IN
genetic/JJ
polymorphisms/NNS
may/MD
be/VB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
HCC/NN
(/(
Chun/NNP
et/FW
al./FW
,/,
2009/CD
;/:
Kim/NN
et/FW
al./FW
,/,
2006/CD
;/:
Oh/RB
et/FW
al./FW
,/,
2008/CD
;/:
Park/NN
et/FW
al./FW
,/,
2006/CD
;/:
Park/NN
et/FW
al./FW
,/,
2007/CD
;/:
Shin/NN
et/FW
al./FW
,/,
2003/CD
;/:
Shin/NN
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
SERPINB5/NN
is/VBZ
one/CD
of/IN
serpins/NNS
and/CC
a/DT
tumor/NN
suppressor/NN
gene/NN
(/(
Sager/NN
et/FW
al./FW
,/,
1997/CD
)/)
,/,
also/RB
commonly/RB
known/VBN
as/IN
maspin/NN
./.
====================
Serpins/NNS
are/VBP
sets/NNS
of/IN
proteins/NNS
that/WDT
are/VBP
able/JJ
to/TO
inhibit/VB
proteases/NNS
and/CC
affect/VB
proteolytic/JJ
cascades/NNS
./.
====================
However/RB
,/,
SERPINB5/NN
is/VBZ
a/DT
special/JJ
case/NN
,/,
which/WDT
acts/VBZ
as/IN
a/DT
tumor/NN
suppressor/NN
gene/NN
instead/RB
of/IN
affecting/VBG
protein/NN
pathways/NNS
./.
====================
SERPINB5/NN
has/VBZ
previously/RB
shown/VBN
the/DT
ability/NN
to/TO
suppress/VB
tumor/NN
cells/NNS
in/IN
places/NNS
such/JJ
as/IN
bones/NNS
,/,
pancreas/NN
,/,
and/CC
esophagus/FW
(/(
Cai/NNP
et/FW
al./FW
,/,
2009/CD
;/:
Hall/NNP
et/FW
al./FW
,/,
2008/CD
;/:
Hong/JJ
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
From/IN
these/DT
findings/NNS
,/,
it/PRP
can/MD
be/VB
inferred/VBN
that/IN
SERPINB5/NN
has/VBZ
a/DT
potent/JJ
ability/NN
to/TO
suppress/VB
tumor/NN
cells/NNS
./.
====================
It/PRP
has/VBZ
also/RB
been/VBN
reported/VBN
that/IN
SERPINB12/NN
,/,
a/DT
member/NN
of/IN
SERPIN/NN
family/NN
and/CC
a/DT
gene/NN
that/WDT
is/VBZ
resided/VBN
right/JJ
next/RB
to/TO
SERPINB5/NN
,/,
is/VBZ
expressed/VBN
in/IN
liver/NN
(/(
Askew/NN
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
SEPRINB12/NN
also/RB
affects/VBZ
many/JJ
tissues/NNS
of/IN
body/NN
,/,
including/VBG
pancreas/NN
and/CC
bone/NN
marrows/VBZ
,/,
which/WDT
are/VBP
same/JJ
parts/NNS
that/DT
are/VBP
affected/VBN
by/IN
SERPINB5/NN
./.
====================
Therefore/RB
,/,
we/PRP
can/MD
also/RB
infer/VBP
that/IN
SERPINB5/NN
may/MD
affect/VB
liver/NN
as/IN
well/RB
./.
====================
As/IN
mentioned/VBN
above/JJ
,/,
genetic/JJ
change/NN
may/MD
be/VB
a/DT
factor/NN
of/IN
HCC/NN
carcinogenesis/NN
,/,
so/RB
we/PRP
hypothesized/VBD
that/IN
genetic/JJ
polymorphisms/NNS
of/IN
SERPINB5/NN
could/MD
influence/VB
HBV/NN
clearance/NN
or/CC
HCC/NN
development/NN
of/IN
HBV/NN
infected/JJ
patients/NNS
./.
====================
A/DT
total/JJ
of/IN
1,074/NN
Korean/JJ
subjects/NNS
having/VBG
either/CC
present/JJ
or/CC
past/JJ
evidence/NN
of/IN
HBV/NN
infection/NN
were/VBD
prospectively/RB
enrolled/JJ
from/IN
the/DT
outpatient/JJ
clinic/JJ
of/IN
the/DT
liver/NN
unit/NN
or/CC
from/IN
the/DT
Center/JJ
for/IN
Health/NN
Promotion/NN
of/IN
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
between/IN
January/NN
2001/CD
and/CC
August/NNP
2003/CD
./.
====================
Subjects/NNS
were/VBD
placed/VBN
in/IN
two/CD
different/JJ
groups/NNS
according/VBG
to/TO
serologic/JJ
markers/NNS
:/:
the/DT
chronic/JJ
carrier/NN
(/(
CC/NN
)/)
group/NN
,/,
or/CC
the/DT
spontaneous/JJ
recovery/NN
(/(
SR/JJ
)/)
group/NN
./.
====================
The/DT
CC/NN
and/CC
SR/JJ
cohorts/NNS
consisted/VBD
of/IN
639/CD
and/CC
435/CD
subjects/NNS
,/,
respectively/RB
(/(
Table/JJ
1/CD
)/)
./.
====================
The/DT
diagnoses/NNS
of/IN
the/DT
CC/NN
and/CC
SR/JJ
subjects/NNS
were/VBD
established/VBN
by/IN
repeated/VBN
seropositivity/NN
for/IN
the/DT
hepatitis/NN
B/NN
surface/NN
antigen/NN
(/(
HBsAg/NN
)/)
(/(
EnzygnostⓇ/NNP
HBsAg/NN
5.0/CD
;/:
Dade/NNP
Behring/VBG
,/,
Marburg/NNP
,/,
Germany/NNP
)/)
over/IN
a/DT
6-month/JJ
period/NN
,/,
and/CC
for/IN
both/DT
anti-HBs/JJ
(/(
EnzygnostⓇ/NNP
Anti-HBs/JJ
II/CD
;/:
Dade/NNP
Behring/VBG
,/,
Marburg/NNP
,/,
Germany/NNP
)/)
and/CC
anti-HBc/JJ
(/(
AB-Corek/NNP
;/:
DiaSorin/NN
s./CC
r./NNP
l./FW
,/,
Saluggia/NNP
,/,
Italy/RB
)/)
of/IN
the/DT
IgG/NN
type/NN
without/IN
HBsAg/NN
,/,
respectively/RB
./.
====================
Asymptomatic/JJ
HBV/NN
carriers/NNS
were/VBD
also/RB
included/VBD
in/IN
CC/NN
group/NN
./.
====================
These/DT
patients/NNS
usually/RB
have/VBP
inactive/JJ
liver/NN
disease/NN
on/IN
liver/NN
biopsy/NN
./.
====================
However/RB
,/,
it/PRP
has/VBZ
been/VBN
known/VBN
that/IN
in/IN
these/DT
patients/NNS
,/,
HBV/NN
continues/NNS
to/TO
replicate/VB
,/,
albeit/IN
very/RB
low/JJ
levels/NNS
,/,
some/DT
patients/NNS
have/VBP
residual/JJ
liver/NN
disease/NN
,/,
and/CC
HCC/NN
develop/VBP
frequently/RB
./.
====================
We/PRP
excluded/VBD
subjects/NNS
who/WP
were/VBD
positive/JJ
for/IN
anti-HBs/JJ
but/CC
not/RB
for/IN
anti-HBc/JJ
,/,
and/CC
those/DT
positive/JJ
for/IN
antiHCV/JJ
or/CC
antiHIV/JJ
(/(
GENEDIAⓇ/NNP
;/:
Greencross/NNP
Life/NN
Science/NNP
Corp./NNP
,/,
Yonginshi/NNP
,/,
Korea/NN
,/,
HCVⓇ3.2/NN
;/:
DongA/NNP
Pharmaceutical/JJ
Co./NNP
,/,
Seoul/JJ
,/,
Korea/NN
)/)
./.
====================
The/DT
patients/NNS
who/WP
had/VBD
any/DT
other/JJ
types/NNS
of/IN
liver/NN
disease/NN
such/JJ
as/IN
autoimmune/JJ
hepatitis/NN
,/,
toxic/JJ
hepatitis/NN
,/,
primary/JJ
biliary/JJ
cirrhosis/NN
,/,
or/CC
Budd/JJ
Chiari/NNP
syndrome/NN
were/VBD
also/RB
excluded/VBN
./.
====================
No/DT
patients/NNS
had/VBD
a/DT
previous/JJ
history/JJ
of/IN
immunosuppression/NN
or/CC
antiviral/JJ
treatment/NN
./.
====================
Informed/VBN
consent/JJ
was/VBD
obtained/VBN
from/IN
each/DT
patient/NN
,/,
and/CC
the/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
Human/JJ
Research/NN
at/IN
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
approved/JJ
the/DT
study/NN
protocol/NN
./.
====================
The/DT
clinical/JJ
parameters/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
In/IN
order/NN
to/TO
discover/RB
genetic/JJ
variants/NNS
,/,
we/PRP
have/VBP
sequenced/VBN
exons/NNS
and/CC
their/PRP$
flanking/JJ
regions/NNS
,/,
including/VBG
the/DT
promoter/NN
region/NN
(/(
1.4/CD
kb/NN
)/)
in/IN
24/CD
Korean/NN
unrelated/JJ
individual/JJ
DNA/NN
samples/NNS
using/VBG
the/DT
ABI/NN
PRISM/NN
3700/CD
DNA/NN
analyzer/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
)/)
./.
====================
Primer/NN
sets/NNS
for/IN
the/DT
amplification/NN
and/CC
sequencing/NN
analysis/NN
of/IN
SERPINB5/NN
were/VBD
designed/VBN
based/VBN
on/IN
GenBank/NN
sequences/NNS
(/(
Ref/NN
./.
====================
Genome/NN
seq/NN
./.
====================
;/:
NC_000018.9/CD
)/)
./.
====================
Sequence/NN
analysis/NN
was/VBD
carried/VBN
out/RP
using/VBG
SeqManⓇ/NN
software/JJ
./.
====================
For/IN
genotyping/VBG
of/IN
eleven/JJ
polymorphic/JJ
sites/NNS
,/,
amplifying/VBG
primers/NNS
and/CC
probes/NNS
were/VBD
designed/VBN
for/IN
TaqManⓇ/NN
(/(
An/DT
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Primer/NN
Express/NN
(/(
Applied/VBN
Biosystems/NNS
)/)
was/VBD
used/VBN
to/TO
design/VB
both/CC
the/DT
PCR/NN
primers/NNS
and/CC
the/DT
MGB/NN
TaqMan/NN
probes/NNS
./.
====================
One/CD
allelic/JJ
probe/NN
was/VBD
labeled/VBN
with/IN
the/DT
FAM/NN
dye/NN
and/CC
the/DT
other/JJ
with/IN
the/DT
fluorescent/JJ
VIC/NN
dye/NN
./.
====================
These/DT
probes/NNS
are/VBP
listed/VBN
in/IN
Supplement/JJ
Table/JJ
1/CD
./.
====================
Typically/RB
,/,
PCR/NN
was/VBD
run/JJ
in/IN
the/DT
TaqMan/NN
Universal/JJ
Master/NN
mix/JJ
without/IN
UNG/NN
(/(
Applied/VBN
Biosystems/NNS
)/)
at/IN
primer/NN
concentration/NN
of/IN
900/CD
nM/NN
and/CC
TaqMan/NN
MGBprobe/NN
concentration/NN
of/IN
200/CD
nM/NN
./.
====================
The/DT
reaction/NN
was/VBD
performed/VBN
in/IN
a/DT
384-well/JJ
format/IN
in/IN
a/DT
total/JJ
reaction/NN
volume/NN
of/IN
5/CD
ul/NN
using/VBG
20/CD
ng/NN
of/IN
genomic/JJ
DNA/NN
./.
====================
The/DT
plate/JJ
was/VBD
then/RB
placed/VBN
in/IN
a/DT
thermal/JJ
cycler/NN
(/(
PE/NN
9700/CD
,/,
Applied/VBN
Biosystems/NNS
)/)
and/CC
heated/JJ
for/IN
2/CD
min/NN
at/IN
50oC/JJ
and/CC
for/IN
10/CD
min/NN
at/IN
95oC/JJ
,/,
followed/VBN
by/IN
40/CD
cycles/NNS
of/IN
95oC/JJ
for/IN
15/CD
s/NNS
and/CC
60oC/JJ
for/IN
1/CD
min/NN
./.
====================
The/DT
TaqMan/NN
assay/NN
plate/VBP
was/VBD
then/RB
transferred/VBD
to/TO
a/DT
Prism/NN
7900HT/CD
instrument/JJ
(/(
Applied/VBN
Biosystems/NNS
)/)
where/WRB
the/DT
fluorescence/NN
intensity/NN
of/IN
each/DT
well/RB
was/VBD
read/VBN
./.
====================
Fluorescence/NN
data/NNS
files/NNS
from/IN
each/DT
plate/NN
were/VBD
analyzed/VBN
by/IN
automated/JJ
software/JJ
(/(
SDS/NN
2.1/CD
)/)
./.
====================
Primer/NN
sequences/NNS
are/VBP
listed/VBN
in/IN
Supplement/JJ
Table/JJ
2/CD
./.
====================
We/PRP
examined/VBD
Lewontin/NN
’/CD
s/NNS
D/NN
’/CD
(/(
|D/NN
’/CD
|/CD
)/)
and/CC
LD/NN
coefficient/JJ
r2/NN
between/IN
all/DT
pairs/NNS
of/IN
biallelic/JJ
loci/NNS
(/(
Hedrick/JJ
,/,
1987/CD
)/)
./.
====================
Haplotypes/NNS
of/IN
each/DT
individual/JJ
were/VBD
inferred/VBN
using/VBG
the/DT
algorithm/NN
(/(
PHASE/NN
)/)
developed/VBD
by/IN
Stephens/NNS
et/FW
al/JJ
./.
====================
(/(
Stephens/NNS
et/FW
al./FW
,/,
2001/CD
)/)
,/,
which/WDT
uses/VBZ
a/DT
Bayesian/JJ
approach/NN
incorporating/VBG
a/DT
priori/JJ
expectations/NNS
of/IN
haplotypic/JJ
structure/NN
from/IN
population/NN
genetic/JJ
and/CC
coalescent/JJ
theory/JJ
./.
====================
Genetic/JJ
effects/NNS
of/IN
inferred/JJ
haplotypes/NNS
were/VBD
analyzed/VBN
in/IN
the/DT
same/JJ
way/NN
as/IN
SNPs/NNS
./.
====================
Logistic/JJ
regression/NN
models/NNS
were/VBD
used/VBN
for/IN
calculating/JJ
odds/NNS
ratios/NNS
(/(
95/CD
%/NN
confidential/JJ
interval/JJ
)/)
and/CC
corresponding/JJ
pvalues/NNS
controlling/VBG
for/IN
age/NN
(/(
continuous/JJ
value/NN
)/)
and/CC
sex/NN
(/(
male=0/NN
,/,
female=1/NN
)/)
as/IN
covariates/VBZ
./.
====================
In/IN
our/PRP$
analysis/NN
of/IN
HCC/NN
occurrence/NN
,/,
LC/NN
(/(
LC=1/NN
,/,
no/DT
LC=0/NN
)/)
and/CC
HBeAg/NN
(/(
negative=0/CD
,/,
blank=1/NN
,/,
positive=2/NN
)/)
were/VBD
also/RB
used/VBN
as/IN
covariates/VBZ
./.
====================
Cox/NN
models/NNS
were/VBD
used/VBN
for/IN
calculating/JJ
relative/JJ
hazards/VBZ
and/CC
Pvalues/NNS
controlling/VBG
for/IN
sex/NN
,/,
adjusted/VBN
age/NN
(/(
0/CD
,/,
＜40/CD
;/:
1/LS
,/,
40∼60/CD
;/:
and/CC
2/CD
,/,
＞60/CD
;/:
classification/NN
factor/NN
)/)
,/,
LC/NN
(/(
Liver/RB
Cirrhosis/NN
)/)
(/(
LC=0/NN
,/,
no/DT
LC=1/NN
;/:
classification/NN
factor/NN
)/)
and/CC
HBeAg/NN
(/(
negative=0/CD
,/,
positive=1/RB
;/:
classification/NN
factor/NN
)/)
./.
====================
In/IN
order/NN
to/TO
achieve/VB
the/DT
optimal/JJ
correction/NN
for/IN
multiple/JJ
testing/VBG
of/IN
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
in/IN
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
with/IN
each/DT
other/JJ
,/,
the/DT
effective/JJ
number/NN
of/IN
independent/JJ
marker/NN
loci/NNS
(/(
9.997/CD
)/)
in/IN
SERPINB5/NN
was/VBD
calculated/VBN
using/VBG
the/DT
software/JJ
,/,
on/IN
the/DT
basis/NN
of/IN
the/DT
spectral/JJ
decomposition/NN
(/(
SpD/NN
)/)
of/IN
matrices/NNS
of/IN
pair-wise/JJ
LD/NN
between/IN
SNPs/NNS
(/(
http/NN
:/:
//genepi/NNP
./.
====================
qimr/RB
./.
====================
edu/DT
./.
====================
au//IN
general/daleN/SNPSpD//JJ
)/)
./.
====================
Statistical/JJ
power/JJR
is/VBZ
calculated/VBN
with/IN
PGA/NN
matlab/NN
application/NN
(/(
Menashe/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
PGA/NN
is/VBZ
an/DT
application/NN
specifically/RB
designed/VBN
to/TO
calculate/VB
statistical/JJ
power/JJR
and/CC
other/JJ
values/NNS
of/IN
casecontrol/JJ
genetic/JJ
association/NN
studies/NNS
./.
====================
For/IN
the/DT
present/JJ
study/NN
,/,
a/DT
codominant/JJ
(/(
1df/NN
)/)
model/NN
with/IN
relative/JJ
risk/NN
1.3/CD
,/,
disease/NN
prevalence/NN
value/NN
7.1/CD
%/NN
(/(
Lee/NNP
et/FW
al./FW
,/,
1998/CD
;/:
Vildozola/NNP
Gonzales/NNS
&/CC
Salinas/NN
,/,
2009/CD
)/)
,/,
EDF/NN
(/(
Effective/JJ
Degree/NNP
of/IN
Freedom/JJ
)/)
2/CD
,/,
and/CC
alpha/NN
error/JJ
level/NN
5/CD
%/NN
were/VBD
used/VBN
to/TO
calculate/JJ
the/DT
statistical/JJ
power/JJR
./.
====================
There/EX
were/VBD
32/CD
observed/VBN
polymorphisms/NNS
in/IN
SERPINB5/NN
,/,
and/CC
11/CD
of/IN
them/PRP
were/VBD
selected/VBN
to/TO
be/VB
genotyped/VBN
in/IN
a/DT
larger/RBR
samples/NNS
(/(
n=1,074/NN
)/)
based/VBN
on/IN
their/PRP$
minor/JJ
allele/NN
frequencies/NNS
(/(
MAF/NN
)/)
,/,
linkage/NN
disequilibriums/NNS
(/(
LD/NN
)/)
,/,
and/CC
locations/NNS
./.
====================
The/DT
SNPs/NNS
selected/VBN
are/VBP
rs62099999/CD
,/,
rs55958273/NN
,/,
rs17071138/NN
,/,
rs57171297/NN
,/,
rs3744940/CD
in/IN
promoter/NN
region/NN
,/,
rs2292294/NN
in/IN
Exon/JJ
3/CD
,/,
rs12454742/NN
in/IN
Exon/JJ
5/CD
,/,
rs2289520/NN
in/IN
Exon/JJ
6/CD
,/,
and/CC
rs1455556/NN
,/,
rs1455555/NN
,/,
rs11542560/CD
in/IN
Exon/JJ
8/CD
(/(
Fig/NN
./.
====================
1A/NN
and/CC
Table/JJ
2/CD
)/)
./.
====================
Some/DT
of/IN
the/DT
polymorphisms/NNS
located/JJ
in/IN
exon/NN
induced/VBD
amino/NN
acid/NN
change/NN
,/,
and/CC
they/PRP
were/VBD
rs2292294/RB
(/(
alanine/NN
at/IN
12/CD
to/TO
alanine/NN
)/)
,/,
rs12454742/RB
(/(
proline/NN
at/IN
111/CD
into/IN
proline/NN
)/)
,/,
rs2289520/RB
(/(
valine/NN
at/IN
187/CD
into/IN
leucine/NN
)/)
,/,
rs1455556/NN
(/(
serine/NN
at/IN
298/CD
into/IN
serine/NN
)/)
,/,
and/CC
rs1455555/NN
(/(
valine/NN
at/IN
319/CD
into/IN
isoleucine/NN
)/)
(/(
Table/JJ
2/CD
)/)
./.
====================
MAFs/NNS
of/IN
each/DT
polymorphism/NN
are/VBP
also/RB
shown/VBN
on/IN
Fig/NN
./.
====================
1A/NN
and/CC
Table/JJ
2/CD
,/,
and/CC
the/DT
statistical/JJ
powers/NNS
for/IN
each/DT
polymorphism/NN
are/VBP
shown/VBN
in/IN
Table/JJ
3/CD
./.
====================
The/DT
frequencies/NNS
of/IN
haplotypes/NNS
are/VBP
listed/VBN
in/IN
Fig/NN
./.
====================
1B/NN
,/,
and/CC
haplotype/NN
p-values/NNS
and/CC
association/NN
analyses/NNS
of/IN
HBV/NN
clearance/NN
and/CC
HCC/NN
occurrence/NN
are/VBP
listed/VBN
in/IN
Table/JJ
3/CD
./.
====================
There/EX
were/VBD
six/CD
major/JJ
haplotypes/NNS
with/IN
MAF/NN
bigger/JJR
than/IN
0.05/CD
,/,
which/WDT
accounted/VBD
for/IN
74.6/CD
%/NN
of/IN
total/JJ
distribution/NN
./.
====================
LDs/NNS
among/IN
the/DT
polymorphisms/NNS
of/IN
SERPINB5/NN
are/VBP
listed/VBN
in/IN
Fig/NN
./.
====================
1C/NN
./.
====================
Association/NN
analyses/NNS
results/VBZ
of/IN
SERPINB5/NN
for/IN
HBV/NN
clearance/NN
are/VBP
shown/VBN
in/IN
Table/JJ
3/CD
./.
====================
There/EX
was/VBD
no/DT
significant/JJ
association/NN
found/VBN
with/IN
SNPs/NNS
and/CC
haplotypes/NNS
in/IN
the/DT
case/NN
of/IN
HBV/NN
clearance/NN
(/(
p＞0.05/NN
)/)
./.
====================
The/DT
results/NNS
for/IN
HCC/NN
occurrence/NN
initially/RB
had/VBD
two/CD
associations/NNS
found/VBN
,/,
with/IN
the/DT
rs17071138/NN
(/(
p=0.05/NN
,/,
OR=0.58/CD
,/,
95/CD
%/NN
CI/NN
(/(
0.34∼0.99/CD
)/)
)/)
and/CC
one/CD
of/IN
the/DT
haplotypes/NNS
,/,
SEPIRNB5/NN
ht5/NN
(/(
[/(
A-T-T-G-C-T-C-C-C-T-A-T/NN
]/)
)/)
(/(
p=0.005/NN
,/,
OR=2.26/NN
,/,
95/CD
%/NN
CI/NN
(/(
1.28∼3.99/CD
)/)
)/)
./.
====================
The/DT
initial/JJ
association/NN
disappeared/VBN
for/IN
rs17071138/NN
when/WRB
the/DT
p-value/JJ
was/VBD
adjusted/VBN
for/IN
the/DT
multiple/JJ
testing/VBG
(/(
correction/NN
value=9.997/NN
)/)
,/,
but/CC
ht5/NN
retained/VBD
the/DT
association/NN
ever/RB
after/IN
the/DT
correction/NN
(/(
PCor=0.05/NN
)/)
./.
====================
However/RB
,/,
the/DT
statistical/JJ
power/JJR
and/CC
MAF/NN
of/IN
ht5/NN
was/VBD
low/JJ
for/IN
the/DT
data/NNS
to/TO
be/VB
completely/RB
trustworthy/JJ
(/(
statistical/JJ
power=40.8/NN
%/NN
,/,
MAF=0.052/NN
)/)
./.
====================
To/TO
analyze/VB
the/DT
role/NN
of/IN
SERPINB5/NN
polymorphisms/NNS
in/IN
the/DT
onset/NN
age/NN
of/IN
HCC/NN
,/,
Cox/NN
relative/JJ
hazards/VBZ
analysis/NN
for/IN
age/NN
of/IN
HCC/NN
occurrence/NN
was/VBD
run/JJ
for/IN
CC/NN
groups/NNS
./.
====================
There/EX
were/VBD
no/DT
significant/JJ
associations/NNS
observed/VBN
after/IN
correction/NN
for/IN
the/DT
multiple/JJ
testing/VBG
(/(
Table/JJ
3/CD
)/)
./.
====================
SERPINB5/NN
has/VBZ
been/VBN
associated/VBN
with/IN
prostate/NN
cancer/NN
,/,
breast/NN
cancer/NN
(/(
Shao/NNP
et/FW
al./FW
,/,
2008/CD
)/)
,/,
pancreas/NN
cancer/NN
(/(
Kashima/NNP
et/FW
al./FW
,/,
2008/CD
;/:
Maass/NNP
et/FW
al./FW
,/,
2001/CD
)/)
and/CC
various/JJ
types/NNS
of/IN
carcinomas/NNS
(/(
Bal/JJ
et/FW
al./FW
,/,
2008/CD
;/:
Blandamura/NNP
et/FW
al./FW
,/,
2006/CD
;/:
Cai/NNP
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
Also/RB
,/,
SERPINB12/NN
,/,
a/DT
member/NN
of/IN
SERPIN/NN
family/NN
and/CC
a/DT
gene/NN
placed/VBN
next/RB
to/TO
SERPINB5/NN
,/,
is/VBZ
expressed/VBN
in/IN
liver/NN
,/,
among/IN
various/JJ
parts/NNS
of/IN
body/NN
(/(
Askew/NN
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
The/DT
gene/NN
has/VBZ
been/VBN
discovered/VBN
in/IN
relatively/RB
recent/JJ
time/NN
(/(
Khalkhali-Ellis/NN
,/,
2006/CD
)/)
,/,
so/RB
there/EX
are/VBP
still/RB
unknown/JJ
facts/NNS
about/RB
SERPINB5/NN
,/,
which/WDT
implies/VBZ
that/IN
SERPINB5/NN
may/MD
have/VB
unidentified/JJ
function/NN
and/CC
effects/NNS
helpful/JJ
for/IN
human/JJ
population/NN
./.
====================
From/IN
this/DT
reasoning/VBG
,/,
the/DT
gene/NN
was/VBD
selected/VBN
to/TO
examine/VB
whether/IN
it/PRP
has/VBZ
relations/NNS
with/IN
HBV/NN
and/CC
HCC/NN
./.
====================
Polymorphisms/NNS
of/IN
SERPINB5/NN
were/VBD
screened/VBN
and/CC
11/CD
variants/NNS
were/VBD
selected/VBN
to/TO
test/VB
their/PRP$
relations/NNS
with/IN
HBV/NN
clearance/NN
and/CC
HCC/NN
occurrence/NN
./.
====================
There/EX
were/VBD
no/DT
significant/JJ
associations/NNS
found/VBN
between/IN
HBV/NN
clearance/NN
and/CC
the/DT
genetic/JJ
polymorphisms/NNS
./.
====================
SERPINB5/NN
is/VBZ
primarily/RB
known/VBN
as/IN
a/DT
tumor/NN
suppressor/NN
gene/NN
,/,
so/RB
the/DT
result/NN
is/VBZ
reasonable/JJ
in/IN
that/DT
HBV/NN
infection/NN
is/VBZ
just/RB
a/DT
precursor/NN
of/IN
HCC/NN
./.
====================
In/IN
the/DT
case/NN
of/IN
HCC/NN
occurrence/NN
analysis/NN
,/,
ht5/NN
showed/VBD
some/DT
relations/NNS
in/IN
co-dominant/JJ
model/NN
(/(
p=0.005/NN
,/,
PCor=0.05/NN
,/,
OR=2.26/NN
,/,
95/CD
%/NN
CI/NN
(/(
1.28∼3.99/CD
)/)
)/)
./.
====================
By/IN
looking/VBG
at/IN
this/DT
result/NN
only/RB
,/,
it/PRP
would/MD
mean/NN
that/DT
ht5/NN
has/VBZ
association/NN
with/IN
HCC/NN
occurrence/NN
./.
====================
However/RB
,/,
although/IN
ht5/NN
showed/VBD
association/NN
with/IN
HCC/NN
occurrence/NN
,/,
it/PRP
had/VBD
a/DT
low/JJ
statistical/JJ
power/JJR
(/(
40.8/CD
%/NN
)/)
and/CC
haplotype/JJ
frequency/NN
(/(
0.052/CD
)/)
,/,
meaning/VBG
the/DT
susceptible/JJ
population/NN
was/VBD
of/IN
a/DT
small/JJ
size/NN
and/CC
unreliable/JJ
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
still/RB
unsure/JJ
whether/IN
ht5/NN
really/RB
had/VBD
an/DT
association/NN
with/IN
HCC/NN
occurrence/NN
or/CC
was/VBD
just/RB
a/DT
false/JJ
positive/JJ
association/NN
,/,
thus/RB
the/DT
association/NN
may/MD
need/RB
to/TO
be/VB
studied/VBN
again/RB
in/IN
the/DT
future/JJ
with/IN
bigger/JJR
sample/JJ
number/NN
,/,
preferably/RB
with/IN
a/DT
higher/JJR
number/NN
of/IN
subjects/NNS
that/DT
exhibit/VBP
ht5/NN
haplotypes/NNS
./.
====================
Although/IN
SEPRINB5/NN
functions/NNS
as/IN
a/DT
tumor/NN
suppressor/NN
gene/NN
in/IN
other/JJ
parts/NNS
of/IN
body/NN
as/IN
mentioned/VBN
above/IN
,/,
association/NN
analyses/NNS
show/VBP
that/IN
it/PRP
does/VBZ
not/RB
play/VB
a/DT
significant/JJ
role/NN
in/IN
the/DT
case/NN
of/IN
HBV/NN
clearance/NN
or/CC
HCC/NN
occurrence/NN
overall/JJ
,/,
at/IN
least/JJS
in/IN
the/DT
genetic/JJ
polymorphisms/NNS
we/PRP
studied/VBD
./.
====================
In/IN
summary/NN
,/,
11/CD
SNPs/NNS
of/IN
SEPRINB5/NN
that/DT
were/VBD
tested/VBN
did/VBD
not/RB
have/VB
any/DT
significant/JJ
relations/NNS
with/IN
HBV/NN
clearance/NN
./.
====================
In/IN
the/DT
case/NN
of/IN
HCC/NN
occurrence/NN
,/,
one/CD
of/IN
the/DT
haplotypes/NNS
,/,
ht5/NN
showed/VBD
a/DT
minor/JJ
association/NN
with/IN
HCC/NN
occurrence/NN
,/,
but/CC
there/EX
is/VBZ
a/DT
possibility/NN
that/IN
it/PRP
might/MD
have/VBP
shown/VBN
the/DT
association/NN
due/JJ
to/TO
the/DT
small/JJ
sample/NN
size/NN
and/CC
low/JJ
frequency/NN
value/NN
./.
====================
Therefore/RB
,/,
this/DT
may/MD
need/VB
to/TO
be/VB
further/RBR
studied/VBN
in/IN
the/DT
future/JJ
with/IN
a/DT
bigger/JJR
number/NN
of/IN
subjects/NNS
./.
====================
SERPINB5/NN
still/RB
has/VBZ
potential/JJ
to/TO
be/VB
a/DT
tumor/NN
suppressor/NN
gene/NN
for/IN
other/JJ
parts/NNS
of/IN
the/DT
body/NN
,/,
so/RB
future/JJ
research/NN
may/MD
focus/VB
on/IN
relations/NNS
between/IN
SERPINB5/NN
and/CC
other/JJ
types/NNS
of/IN
cancers/NNS
./.
====================
However/RB
,/,
it/PRP
seems/VBZ
that/DT
SERPINB5/NN
does/VBZ
not/RB
influence/VB
development/NN
of/IN
HCC/NN
or/CC
have/VBP
association/NN
with/IN
HBV/NN
clearance/NN
,/,
at/IN
least/JJS
in/IN
the/DT
studied/VBN
genetic/JJ
polymorphisms/NNS
,/,
although/IN
this/DT
does/VBZ
not/RB
rule/JJ
out/IN
SERPINB5/NN
from/IN
the/DT
candidate/NN
genes/NNS
of/IN
HBV/NN
clearance/NN
or/CC
HCC/NN
occurrence/NN
altogether/RB
,/,
because/IN
there/EX
are/VBP
still/RB
many/JJ
unknown/JJ
aspects/NNS
of/IN
genes/NNS
,/,
and/CC
many/JJ
current/JJ
researches/NNS
are/VBP
focusing/VBG
on/IN
those/DT
aspects/NNS
,/,
such/JJ
as/IN
copy/RB
number/NN
variations/NNS
and/CC
methylations/NNS
of/IN
DNA/NN
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
premature/JJ
to/TO
say/VB
that/DT
SERPINB5/NN
does/VBZ
not/RB
influence/VB
HBV/NN
clearance/NN
or/CC
HCC/NN
occurrence/NN
on/IN
any/DT
level/NN
./.
====================
